Trial Profile
A phase I, open-label study of SB-715992 [ispinesib] in combination with docetaxel in patients with advanced solid tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Aug 2023
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Ispinesib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors GSK
- 09 Oct 2008 Checked against ClinicalTrials.gov record - last updated 9 October 2008.
- 18 Sep 2007 Status changed from in progress to completed.
- 05 Jan 2007 Status change